OncoResponse, a Houston-based immuno-oncology antibody discovery company, raised $7m in a supplemental Series A financing.
The round consisted of a $3.5m investment from GreatPoint Ventures and a $3.5m investment from the Helsinn Investment Fund.
The company – which has raised to $19.5m to date, intends to use the funds to increase its ongoing efforts to interrogate the humoral response of elite responders to cancer immunotherapy to identify antibodies and potential targets for novel therapeutic development.
Led by Clifford J. Stocks, CEO, OncoResponse utilizes a clinically validated platform technology to screen antibodies made by the human immune system and identify those with exceptional reactivity to cancer immunotherapy. The company has an ongoing strategic alliance with the MD Anderson Cancer Center, which provides access to patient samples and oncology and translational medicine expertise including clinical and regulatory input.